Last updated: 02/18/2020 07:50:06
A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis
Trial description: The purpose of this study is to evaluate the safety and the immunogenicity of two different doses of the GVGH S. sonnei vaccine in healthy adults and represents the first step towards testing of the GMMA vaccine in the vaccine target population of children from developing countries where shigellosis is endemic.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of subjects with solicited local and systemic adverse reactions after each vaccination
Timeframe: From 30 minutes up to 7 days following each vaccination
Number of subjects with any unsolicited adverse events (AEs)
Timeframe: During 28 days following each vaccination
Number of subjects with serious adverse events (SAEs)
Timeframe: Throughout the whole study period (from Day 1 up to Day 57)
Number of subjects with deviations from normal ranges of safety laboratory data at Day 8 by baseline ranges
Timeframe: At Day 8 (7 days after first vaccination)
Number of subjects with deviations from normal ranges of safety laboratory data at Day 29 by baseline ranges
Timeframe: At Day 29 (28 days after the first vaccination)
Number of subjects with deviations from normal ranges of safety laboratory data at Day 36 by baseline ranges
Timeframe: At Day 36 (7 days after the second vaccination)
Number of subjects with deviations from normal ranges of safety laboratory data at Day 57 by baseline ranges
Timeframe: At Day 57 (28 days after the second vaccination)
Number of subjects with reported reactive arthritis or neutropenia (AESIs)
Timeframe: Throughout the whole study period (from Day 1 up to Day 57)
Secondary outcomes:
Anti-LPS S.Sonnei IgG ELISA geometric mean concentrations (GMCs), by baseline titer
Timeframe: At Day 1, Day 29 (28 days after the first vaccination) and Day 57 (28 days after the second vaccination)
Anti-LPS S. sonnei geometric mean ratios (GMRs) between post- and pre-vaccination samples
Timeframe: At Day 1, Day 29 (28 days after the first vaccination) and Day 57 (28 days after the second vaccination)
Number of subjects with seroresponse to anti-LPS S. Sonnei IgG ELISA, by baseline titer
Timeframe: At Day 29 (28 days after the first vaccination) and Day 57 (28 days after the second vaccination)
Number of subjects with titers post vaccination concentration for anti-LPS S. sonnei ≥ 121 U/mL
Timeframe: At Day 1, Day 29 (28 days after the first vaccination) and Day 57 (28 days after the second vaccination)
Interventions:
Biological/vaccine: GVGH S. sonnei (1790GAHB) vaccine 25 μg
Biological/vaccine: GVGH S. sonnei (1790GAHB) vaccine 100 μg
Biological/vaccine: Menveo
Biological/vaccine: Boostrix
Enrollment:
74
Observational study model:
Not applicable
Primary completion date:
2017-10-03
Time perspective:
Not applicable
Clinical publications:
Obiero CW et al. (2017) A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a Shigellosis-endemic country. Front Immunol. 8:1884. doi: 10.3389/fimmu.2017.01884.
Medical condition
Shigella sonnei infection
Product
GSK3536852A
Collaborators
Not applicable
Study date(s)
August 2016 to March 2017
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 45 years
Accepts healthy volunteers
Yes
- 1. Individuals ≥18 years to ≤45 years of age on the day of informed consent who are resident in the study area and are not planning to leave during the study period.
- 2. Individuals who, after the nature of the study has been explained, have voluntarily given written consent according to local regulatory requirements, prior to study entry.
- 1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
- 2. Individuals with any progressive or severe neurological disorder, seizure disorder or previous Guillain-Barré syndrome.
Inclusion and exclusion criteria
Inclusion criteria:
- 1. Individuals ≥18 years to ≤45 years of age on the day of informed consent who are resident in the study area and are not planning to leave during the study period. 2. Individuals who, after the nature of the study has been explained, have voluntarily given written consent according to local regulatory requirements, prior to study entry. 3. Individuals who can comply with study procedures including follow-up. 4. Individuals in good health as determined by the outcome of medical history, physical examination, hematology, renal function, and liver function tests, urine dipstick/urinalysis and the clinical judgment of the investigator. 5. Males Or Females of childbearing potential who are using an effective birth control method which they intend to use for the duration of the study Or Females without childbearing potential (i.e. irrespective of birth control method) Prior to receipt of second study vaccination, subjects must be evaluated to confirm that they are eligible for subsequent vaccination. If subjects do not meet any of the original inclusion criteria listed above, they should not receive additional vaccinations.
Exclusion criteria:
- 1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study. 2. Individuals with any progressive or severe neurological disorder, seizure disorder or previous Guillain-Barré syndrome. 3. Individuals who, in the judgment of the investigator, may not be able to comply with all the required study procedures. 4. Individuals with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study. 5. Individuals with history of reactive arthritis. 6. Individuals with known HIV or hepatitis B virus infection or HIV related disease, history of an autoimmune disorder or any other known or suspected impairment /alteration of the immune system. Individuals under systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to screening. 7. Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time. 8. Individuals with a neutrophil count lower than 1.8 x 10^9/L (applicable to the initial 18 subjects) or lower than 1.0 x 10^9/L (applicable to the additional subjects if approved by DSMB) at screening 9. Individuals with any serious chronic or progressive disease according to judgment of the investigator (e.g., neoplasm, insulin dependent diabetes, Type 2 diabetes mellitus, hypertension, cardiac, renal or hepatic disease and tuberculosis). 10. Individuals who have any malignancy or lymphoproliferative disorder. 11. Individuals with history of allergy to vaccines components or any other allergies deemed by the investigator to increase the risk of an adverse event if they were to participate in the trial. 12. Individuals participating in any clinical trial with another investigational product within 28 days prior to the screening study visit or intent to participate in another clinical study at any time during the conduct of this study. 13. Individuals who received vaccines containing meningococcal A, C, W, Y or tetanus, diphtheria or pertussis antigens within 12 months before screening, or any other vaccines within 4 weeks prior to screening in this study or who are planning to receive any vaccine within the entire study duration. 14. Individuals who have received blood, blood products, and/or plasma derivatives including parenteral immunoglobulin preparations in the 12 weeks prior to the first dose of the study vaccine. 15. Individuals who are study personnel or immediate family members (parents, children, spouse and brothers/sisters) to the personnel conducting this study. 16. Individuals with body temperature > 38.0°C within 3 days of intended study vaccination is a reason for delay of vaccination 17. Individuals with Body Mass Index (BMI)> 30 kg/m^2 18. Individuals with history of substance or alcohol abuse within the past 2 years. 19. Women who are pregnant or are breast-feeding, or are of childbearing age who have not used (for the two months preceding the 1st vaccination) and are not willing to use acceptable contraceptive measures, for the duration of the study. If subjects are women of childbearing potential, they must have a negative pregnancy test at screening visit and prior to enrollment (visit 1). For the purposes of this study acceptable methods of contraception are oral, injected or implantable contraceptives. 20. Individuals who have a previously laboratory confirmed case of disease caused by S. sonnei. 21. Any condition which, in the opinion of the investigator, may pose an increased and unreasonable safety risk to the subject if they participated in the study. 22. Individuals with a previous history of Benign Ethnic Neutropenia or drug related neutropenia. 23. Individuals who have or are likely to require concomitant treatment with neutropenic agents.
Trial location(s)
Study documents
Statistical analysis plan
Available language(s): English
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2017-10-03
Actual study completion date
2017-10-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
IPD for this study will be made available via the Clinical Study Data Request site.
Click hereAccess to clinical trial data by researchers
Visit website